Lincoln Pharma Announces 32nd AGM on Sep 30, 2026, via VC/OAVM
Lincoln Pharmaceuticals Limited will hold its 32nd AGM on September 30, 2026, via VC/OAVM. Shareholders can access the Annual Report 2025-26 online. The company also reminds physical security holders to update KYC details as per SEBI mandate.
This is a standard procedural announcement related to corporate governance and regulatory compliance, unlikely to have a significant immediate impact on the company's stock price.
The announcement is a routine corporate communication regarding the AGM and Annual Report, with no significant financial or business performance indicators mentioned.
Lincoln Pharmaceuticals Limited has announced its 32nd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:00 AM IST through Video Conferencing (VC) facility or Other Audio-Visual Means (OAVM).
The company is also sending letters to shareholders whose email addresses are not registered, providing a web-link and the exact path to access the Notice and the Annual Report for the Financial Year 2025-26 on the company's website.
The web-link for the Annual Report is https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/annual-report/. The exact path is www.lincolnpharma.com >> Investors >> Disclosures under Regulation 46 of the LODR >> Point-17: Annual Reports >> 2025-26.
This communication also serves as a reminder for shareholders holding physical securities to update their KYC details, including PAN, address, mobile number, bank account details, specimen signature, and nomination choice, as mandated by SEBI. Payments like dividends, interest, or redemption will only be made through electronic mode for folios lacking updated KYC details from April 1, 2024.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.